Valuation
- Market cap
- 61,696,000
- Revenue TTM
- $60,000
- Net income TTM
- $-55,480,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -92,466.67%
- Debt to equity
- 0.00
Trading
- Volume
- 4,196,100
- Avg volume
- 4,672,439
- Day's range
- $0.89 – $1.08
- Shares out
- 62,974,000
- Stochastic %K
- 4%
- Beta
- -0.15
- Analysts
- Strong Sell
- Price target
- $5.88
Company profile
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 877 245 2787
- Website
- https://www.connectbiopharm.com
- Address
- 3580 Carmel Mountain Road, Suite 200, San Diego, United States
Latest news
No headlines yet.
